Sector Gamma AS Grows Stake in BioNTech SE Sponsored ADR $BNTX

Sector Gamma AS boosted its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 24.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 37,470 shares of the company's stock after purchasing an additional 7,470 shares during the quarter. Sector Gamma AS's holdings in BioNTech were worth $3,989,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Banque Cantonale Vaudoise purchased a new position in shares of BioNTech in the 1st quarter valued at $36,000. LRI Investments LLC increased its holdings in shares of BioNTech by 234.6% in the 2nd quarter. LRI Investments LLC now owns 445 shares of the company's stock valued at $47,000 after acquiring an additional 312 shares during the period. Banque Transatlantique SA purchased a new position in shares of BioNTech in the 1st quarter valued at $80,000. Costello Asset Management INC purchased a new position in shares of BioNTech in the 1st quarter valued at $91,000. Finally, Goodman Advisory Group LLC purchased a new position in shares of BioNTech in the 1st quarter valued at $105,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Stock Down 1.4%

Shares of BNTX stock opened at $104.75 on Friday. BioNTech SE Sponsored ADR has a 1-year low of $81.20 and a 1-year high of $129.27. The stock's fifty day moving average price is $103.36 and its 200 day moving average price is $104.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The company has a market cap of $25.18 billion, a price-to-earnings ratio of -65.47 and a beta of 1.45.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The firm had revenue of $306.46 million for the quarter, compared to analysts' expectations of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm's revenue for the quarter was up 102.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. On average, research analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BNTX. Morgan Stanley cut their price target on BioNTech from $133.00 to $131.00 and set an "overweight" rating on the stock in a report on Friday, October 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of BioNTech in a report on Tuesday, October 14th. HC Wainwright reiterated a "buy" rating and issued a $136.00 price target on shares of BioNTech in a report on Monday, September 8th. JPMorgan Chase & Co. dropped their target price on BioNTech from $121.00 to $120.00 and set a "neutral" rating on the stock in a research note on Thursday. Finally, Bank of America dropped their target price on BioNTech from $134.00 to $130.00 and set a "buy" rating on the stock in a research note on Wednesday. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $133.96.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.